

COVID-19 Vaccination: Building Global Capacity

Q&A for Session 12: Microplanning and Supportive Supervision

Tuesday, May 4, 2021

Thank you for attending the above session for National, regional and global stakeholders. Many questions were submitted by participants, either in the Zoom chat during the session itself, or in the two Telegram channels managed by Technet-21 supporting regions, countries, and partners in preparing for COVID-19 vaccine introduction. In this document, we share the answers from presenters to each question.

Links to the session recordings in all languages and presentations can be found on the [Project ECHO website](#).

More information on COVID-19 vaccine introduction can be found in the resources listed below.

- [General questions regarding the COVID-19 vaccines](#)
- [Preparing for COVID-19 vaccination](#)
- [WHO Coronavirus disease \(COVID-2019\) technical guidance](#)
- [TechNet-21 – The Technical Network for Strengthening Immunization Services](#)
- OpenWHO COVID-19 vaccine trainings:
 - [Orientation to national deployment and vaccination planning for COVID-19 vaccines](#)

In addition, TechNet-21 manages two Telegram channels supporting regions, countries, and partners in preparing for COVID-19 vaccine introduction. In these two spaces - one anglophone and one francophone - you will be able to share your experiences, discuss key questions, and connect with experts from around the world. We'll also share new information and global guidance as it becomes available. Join us today:

- [COVID-19 Vaccine Introduction – TechNet-21 \(English\)](#)
- [Introduction des vaccins contre la Covid-19 – TechNet-21 \(Français\)](#)

What if the SAGE recommendation for prioritization road map is not helping in the required or good coverage?

The SAGE recommendations for prioritization has guided countries to prioritize the high risk groups to be targeted in phases ; the optimum coverage that we want to attain was compromised due to the myths, misinformation and exaggerated social media information on the AZ vaccine where even Health workers were reserved that has contributed.

Noting this, and the short shelf life, countries expanded to the next priority group (elderly and co-morbidities) with inadequate or limited information campaign that may have limited the turnout for the vaccine.